Neuronal regulators and vascular dysfunction in Raynaud's phenomenon and systemic sclerosis

Current Vascular Pharmacology

Volumn 7, Issue 1, 2009, Pages 34-39

  Fonseca, Carmen ^a   Abraham, David ^a   Ponticos, Markella ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Adrenergic receptors; Neuropeptides; Raynaud's phenomenon; Systemic sclerosis; Vasoconstriction

Indexed keywords

CALCITONIN GENE RELATED PEPTIDE; NEUROHORMONE; NEUROPEPTIDE; NEUROPEPTIDE Y; RHO KINASE; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SUBSTANCE P; VASOACTIVE INTESTINAL POLYPEPTIDE;

ADRENERGIC STIMULATION; BLOOD VESSEL TONE; COLD STRESS; EMOTIONAL STRESS; HUMAN; OXIDATION REDUCTION REACTION; PATHOGENESIS; RAYNAUD PHENOMENON; REVIEW; SIGNAL TRANSDUCTION; SKIN BLOOD VESSEL; SYMPATHETIC NERVE; SYSTEMIC SCLEROSIS; VASCULAR DISEASE; VASODILATATION; VASOSPASM; ADRENERGIC SYSTEM; METABOLISM; PATHOPHYSIOLOGY;

HUMANS; OXIDATION-REDUCTION; RAYNAUD DISEASE; RHO-ASSOCIATED KINASES; RHOA GTP-BINDING PROTEIN; SCLERODERMA, SYSTEMIC; SIGNAL TRANSDUCTION; SYMPATHETIC NERVOUS SYSTEM;

EID: 61549125078     PISSN: 15701611     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016109787354105     Document Type: Review

References (66)

1. Bowling JC, Dowd PM. Raynaud's disease. Lancet 2003; 361: 2078-2080.
2. Generini S, Seibold JR, Matucci-Cerinic M. Estrogens and neuropeptides in Raynaud's phenomenon. Rheum Dis Clin North Am 2005; 31: 177-1xi.
3. Boin F, Wigley FM. Understanding, assessing and treating Raynaud's phenomenon. Curr Opin Rheumatol 2005; 17: 752-760.
4. Herrick AL. Pathogenesis of Raynaud's phenomenon. Rheumatology (Oxford) 2005; 44: 587-596.
5. Cooke JP, Marshall JM. Mechanisms of Raynaud's disease. Vasc Med 2005; 10: 293-307.
6. Bukhari M, Herrick AL, Moore T, Manning J, Jayson MI. Increased nailfold capillary dimensions in primary Raynaud's phenomenon and systemic sclerosis. Br J Rheumatol 1996; 35: 1127-1131.
7. Rodnan GP, Myerowitz RL, Justh GO. Morphologic changes in the digital arteries of patients with progressive systemic sclerosis (scleroderma) and Raynaud phenomenon. Medicine (Baltimore) 1980; 59: 393-408.
8. Bollinger A, Schlumpf M. Finger blood flow in healthy subjects of different age and sex and in patients with primary Raynaud's disease. Acta Chir Scand Suppl 1976; 465: 42-47.
9. Cooke JP, Creager MA, Osmundson PJ, Shepherd JT. Sex differences in control of cutaneous blood flow. Circulation 1990; 82: 1607-1615.
10. Freedman RR, Girgis R. Effects of menstrual cycle and race on peripheral vascular alpha-adrenergic responsiveness. Hypertension 2000; 35: 795-799.
11. Bylund DB. Subtypes of alpha 1- and alpha 2-adrenergic receptors. FASEB J 1992; 6: 832-839.
12. Minneman KP, Dibner MD, Wolfe BB, Molinoff PB. beta1- and beta2-Adrenergic receptors in rat cerebral cortex are independently regulated. Science 1979; 204: 866-868.
13. Gingrich JA, Caron MG. Recent advances in the molecular biology of dopamine receptors. Annu Rev Neurosci 1993; 16: 299-321.
14. Rockman HA, Koch WJ, Lefkowitz RJ. Seven-transmembrane-spanning receptors and heart function. Nature 2002; 415: 206-212.
15. Flavahan NA. Regulation of vascular reactivity in scleroderma: new insights into Raynaud's phenomenon. Rheum Dis Clin North Am 2008; 34: 81-87.
16. Flavahan NA, Cooke JP, Shepherd JT, Vanhoutte PM. Human postjunctional alpha-1 and alpha-2 adrenoceptors: differential distribution in arteries of the limbs. J Pharmacol Exp Ther 1987; 241: 361-365.
17. Coffman JD, Cohen RA. Role of alpha-adrenoceptor subtypes mediating sympathetic vasoconstriction in human digits. Eur J Clin Invest 1988; 18: 309-313.
18. Herrick AL, Matucci CM. The emerging problem of oxidative stress and the role of antioxidants in systemic sclerosis. Clin Exp Rheumatol 2001; 19: 4-8.
19. Jeyaraj SC, Chotani MA, Mitra S, Gregg HE, Flavahan NA, Morrison KJ. Cooling evokes redistribution of alpha2C-adrenoceptors from Golgi to plasma membrane in transfected human embryonic kidney 293 cells. Mol Pharmacol 2001; 60: 1195-1200.
20. Hein L, Altman JD, Kobilka BK. Two functionally distinct alpha2-adrenergic receptors regulate sympathetic neurotransmission. Nature 1999; 402: 181-184.
21. Cooke JP, Creager SJ, Scales KM, Ren C, Tsapatsaris NP, Beetham WP, Jr., et al. Role of digital artery adrenoceptors in Raynaud's disease. Vasc Med 1997; 2: 1-7.
22. Block JA, Sequeira W. Raynaud's phenomenon. Lancet 2001; 357: 2042-2048.
23. Bailey SR, Mitra S, Flavahan S, Flavahan NA. Reactive oxygen species from smooth muscle mitochondria initiate cold-induced constriction of cutaneous arteries. Am J Physiol Heart Circ Physiol 2005; 289: H243-H250.
24. Bailey SR, Eid AH, Mitra S, Flavahan S, Flavahan NA. Rho kinase mediates cold-induced constriction of cutaneous arteries: role of alpha2C-adrenoceptor translocation. Circ Res 2004; 94: 1367-1374.
25. Kajimoto H, Hashimoto K, Bonnet SN, Haromy A, Harry G, Moudgil R, et al. Oxygen activates the Rho/Rho-kinase pathway and induces RhoB and ROCK-1 expression in human and rabbit ductus arteriosus by increasing mitochondria-derived reactive oxygen species: a newly recognized mechanism for sustaining ductal constriction. Circulation 2007; 115: 1777-1788.
26. Fukata M, Kaibuchi K. Rho-family GTPases in cadherin-mediated cell-cell adhesion. Nat Rev Mol Cell Biol 2001; 2: 887-897.
27. Somlyo AP, Somlyo AV. Signal transduction through the RhoA/Rho-kinase pathway in smooth muscle. J Muscle Res Cell Motil 2004; 25: 613-615.
28. Flavahan NA, Lindblad LE, Verbeuren TJ, Shepherd JT, Vanhoutte PM. Cooling and alpha 1- and alpha 2-adrenergic responses in cutaneous veins: role of receptor reserve. Am J Physiol 1985; 249: H950-H955.
29. Thompson-Torgerson CS, Holowatz LA, Flavahan NA, Kenney WL. Cold-induced cutaneous vasoconstriction is mediated by Rho kinase in vivo in human skin. Am J Physiol Heart Circ Physiol 2007; 292: H1700-H1705.
30. Liao JK, Seto M, Noma K. Rho kinase (ROCK) inhibitors. J Cardiovasc Pharmacol 2007; 50: 17-24.
31. Rikitake Y, Liao JK. Rho GTPases, statins, and nitric oxide. Circ Res 2005; 97: 1232-1235.
32. Freedman RR, Baer RP, Mayes MD. Blockade of vasospastic attacks by alpha 2-adrenergic but not alpha 1-adrenergic antagonists in idiopathic Raynaud's disease. Circulation 1995; 92: 1448-1451.
33. Suter LG, Murabito JM, Felson DT, Fraenkel L. The incidence and natural history of Raynaud's phenomenon in the community. Arthritis Rheum 2005; 52: 1259-1263.
34. Eid AH, Maiti K, Mitra S, Chotani MA, Flavahan S, Bailey SR, et al. Estrogen increases smooth muscle expression of alpha2C-adrenoceptors and cold-induced constriction of cutaneous arteries. Am J Physiol Heart Circ Physiol 2007; 293: H1955-H1961.
35. McNeill AM, Leslie FM, Krause DN, Duckles SP. Gender difference in levels of alpha2-adrenoceptor mRNA in the rat tail artery. Eur J Pharmacol 1999; 366: 233-236.
36. Fraenkel L, Zhang Y, Chaisson CE, Evans SR, Wilson PW, Felson DT. The association of estrogen replacement therapy and the Raynaud phenomenon in postmenopausal women. Ann Intern Med 1998; 129: 208-211.
37. O'Halloran DJ, Bloom SR. Calcitonin gene related peptide. BMJ 1991; 302: 739-740.
38. Wallengren J, Hakanson R. Effects of substance P, neurokinin A and calcitonin gene-related peptide in human skin and their involvement in sensory nerve-mediated responses. Eur J Pharmacol 1987; 143: 267-273.
39. Gray DW, Marshall I. Nitric oxide synthesis inhibitors attenuate calcitonin gene-related peptide endothelium-dependent vasorelaxation in rat aorta. Eur J Pharmacol 1992; 212: 37-42.
40. Gray DW, Marshall I. Human alpha-calcitonin gene-related peptide stimulates adenylate cyclase and guanylate cyclase and relaxes rat thoracic aorta by releasing nitric oxide. Br J Pharmacol 1992; 107: 691-696.
41. de Hoon JN, Pickkers P, Smits P, Struijker-Boudier HA, Van Bortel LM. Calcitonin gene-related peptide: exploring its vasodilating mechanism of action in humans. Clin Pharmacol Ther 2003; 73: 312-321.
42. Brain SD, Grant AD. Vascular actions of calcitonin gene-related peptide and adrenomedullin. Physiol Rev 2004; 84: 903-934.
43. Bunker CB, Goldsmith PC, Leslie TA, Hayes N, Foreman JC, Dowd PM. Calcitonin gene-related peptide, endothelin-1, the cutaneous microvasculature and Raynaud's phenomenon. Br J Dermatol 1996; 134: 399-406.
44. Bunker CB, Terenghi G, Springall DR, Polak JM, Dowd PM. Deficiency of calcitonin gene-related peptide in Raynaud's phenomenon. Lancet 1990; 336: 1530-1533.
45. Shawket S, Dickerson C, Hazleman B, Brown MJ. Selective suprasensitivity to calcitonin-gene-related peptide in the hands in Raynaud's phenomenon. Lancet 1989; 2: 1354-1357.
46. Terenghi G, Bunker CB, Liu YF, Springall DR, Cowen T, Dowd PM, et al. Image analysis quantification of peptide-immunoreactive nerves in the skin of patients with Raynaud's phenomenon and systemic sclerosis. J Pathol 1991; 164: 245-252.
47. Wallengren J, Akesson A, Scheja A, Sundler F. Occurrence and distribution of peptidergic nerve fibers in skin biopsies from patients with systemic sclerosis. Acta Derm Venereol 1996; 76: 126-128.
48. Shawket S, Dickerson C, Hazleman B, Brown MJ. Prolonged effect of CGRP in Raynaud's patients: a double-blind randomised comparison with prostacyclin. Br J Clin Pharmacol 1991; 32: 209-213.
49. Bunker CB, Reavley C, O'Shaughnessy DJ, Dowd PM. Calcitonin gene-related peptide in treatment of severe peripheral vascular insufficiency in Raynaud's phenomenon. Lancet 1993; 342: 80-83.
50. Szabo A, Czirjak L, Sandor Z, Helyes Z, Laszlo T, Elekes K, et al. Investigation of sensory neurogenic components in a bleomycin-induced scleroderma model using transient receptor potential vanilloid 1 receptor- and calcitonin gene-related peptide-knockout mice. Arthritis Rheum 2008; 58: 292-301.
51. Harrison S, Geppetti P. Substance p. Int J Biochem Cell Biol 2001; 33: 555-576.
52. Tottrup A, Kraglund K. Endothelium-dependent responses in small human mesenteric arteries. Physiol Res 2004; 53: 255-263.
53. Freedman RR, Girgis R, Mayes MD. Abnormal responses to endothelial agonists in Raynaud's phenomenon and scleroderma. J Rheumatol 2001; 28: 119-121.
54. Matucci-Cerinic M, Pietrini U, Marabini S. Local venomotor response to intravenous infusion of substance P and glyceryl trinitrate in systemic sclerosis. Clin Exp Rheumatol 1990; 8: 561-565.
55. Kuo LE, Abe K, Zukowska Z. Stress, NPY and vascular remodeling: Implications for stress-related diseases. Peptides 2007; 28: 435-440.
56. Stephens DP, Saad AR, Bennett LA, Kosiba WA, Johnson JM. Neuropeptide Y antagonism reduces reflex cutaneous vasoconstriction in humans. Am J Physiol Heart Circ Physiol 2004; 287: H1404-H1409.
57. Abe K, Tilan JU, Zukowska Z. NPY and NPY receptors in vascular remodeling. Curr Top Med Chem 2007; 7: 1704-1709.
58. Wheway J, Herzog H, Mackay F. NPY and receptors in immune and inflammatory diseases. Curr Top Med Chem 2007; 7: 1743-1752.
59. Akesson A, Ekman R. Gastrointestinal regulatory peptides in systemic sclerosis. Arthritis Rheum 1993; 36: 698-703.
60. Leppert J, Nilsson H, Myrdal U, Edvinsson L, Hedner T, Ringqvist I. Sympathetic activation after two weeks of nifedipine treatment in primary Raynaud's patients and controls. Cardiovasc Drugs Ther 1993; 7: 901-907.
61. Wilkins BW, Chung LH, Tublitz NJ, Wong BJ, Minson CT. Mechanisms of vasoactive intestinal peptide-mediated vasodilation in human skin. J Appl Physiol 2004; 97: 1291-1298.
62. Matucci-Cerinic M, Giacomelli R, Pignone A, Cagnoni ML, Generini S, Casale R, et al. Nerve growth factor and neuropeptides circulating levels in systemic sclerosis (scleroderma). Ann Rheum Dis 2001; 60: 487-494.
63. Haustein UF, Weber B, Seikowski K. [Substance P and vasoactive intestinal peptide in patients with progressive scleroderma. Determination of plasma level before and after autogenic training]. Hautarzt 1995; 46: 102-106.
64. Kaada B, Lygren I. Lower plasma levels of some gastrointestinal peptides in Raynaud's disease. Influence of transcutaneous nerve stimulation. Gen Pharmacol 1985; 16: 153-156.
65. Danese C, Caiola S, Lucia P, Cedrone L, Colotto M, Arceri D, et al. Relationship among VIP plasma levels, esophageal dysfunction, and microcirculation in systemic sclerosis. Minerva Med 2000; 91: 185-189.
66. Derk CT, Jimenez SA. Statins and the vasculopathy of systemic sclerosis: potential therapeutic agents? Autoimmun Rev 2006; 5: 25-32.